•
Jun 30, 2023
Cocrystal Pharma Q2 2023 Earnings Report
Reported financial results for Q2 2023 and provided updates on its antiviral drug development programs.
Key Takeaways
Cocrystal Pharma reported a net loss of $4.2 million, or $0.41 per share, for the second quarter of 2023. The company's cash position is sufficient to fund planned operations for the next 12 months.
Advanced novel oral PB2 inhibitor CC-42344 for influenza A, submitting an application for UK MHRA approval to begin a Phase 2a human challenge trial.
Received approval from the Australian regulatory agency to begin a first-in-human trial with novel, broad-spectrum oral protease inhibitor CDI-988 for COVID-19.
Selected CDI-988 as the lead oral norovirus candidate.
Expect to report top-line data of CDI-988 Phase 1 study in 2024.
Cocrystal Pharma
Cocrystal Pharma
Forward Guidance
Cocrystal Pharma believes its current cash position is sufficient to fund planned operations for the next 12 months.